IFLI, established as a non-profit organization in February 2022, is driven by a steadfast commitment to forging powerful partnerships that progress the understanding of FL biology and impact treatment options. Our ultimate goal is to find a cure for FL. IFLI is funding a diversified portfolio that caters to the different stages of development, from discovery to patient bed. We are committed to integrating both existing therapeutic approaches and cutting-edge technologies into our dynamic portfolio.
External link for IFLI - Institute for Follicular Lymphoma Innovation
1440 Bridgegate Dr
Diamond Bar, California 91765, US
IFLI - Institute for Follicular Lymphoma Innovation reposted this
Innate Pharma together with the IFLI - Institute for Follicular Lymphoma Innovation today announced that they have entered into an agreement to clinically study the potential of IPH6501, a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 ANKET® in #follicular #lymphoma (FL). 👏 https://lnkd.in/eUPv-Ejk
Fantastic work! Bravo
Oral communication at the ASH meeting about Hodgkin lymphoma (second part)! I’m thrilled to announce the presentation of the second part of our work today at 2.45 pm Pacific time (a collaborative research project between the LYSA group and Ash ALizadeh 's group at Stanford ) regarding multimodal genomic profiling (mutations, copy numbers, TCR repertoire, viral profiling including multiple viruses, gene expression inferred by EPIC-Seq) from LYSA trials and CHU Dijon-Bourgogne!
Delighted to ink IFLI - Institute for Follicular Lymphoma Innovation’s investment to expand Innate Pharma’s Phase 1/2 IPH6501 to #follicularlymphoma.
Innate Pharma together with the IFLI - Institute for Follicular Lymphoma Innovation today announced that they have entered into an agreement to clinically study the potential of IPH6501, a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 ANKET® in #follicular #lymphoma (FL). 👏 https://lnkd.in/eUPv-Ejk
Innate Pharma together with the IFLI - Institute for Follicular Lymphoma Innovation today announced that they have entered into an agreement to clinically study the potential of IPH6501, a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 ANKET® in #follicular #lymphoma (FL). 👏 https://lnkd.in/eUPv-Ejk
If you will be at ASH, we'd love to invite you to join us at our hosted luncheon on Sat Dec 7 - please feel free to register and share with others who may be interested as well.
Join IFLI at the American Society of Hematology (ASH) Annual Meeting. We’re thrilled to be attending ASH2024! We look forward to collaborating with the leading minds in #hematology to support the latest in innovations and breakthroughs in the industry. The IFLI - Institute for Follicular Lymphoma Innovation team will be hosting a luncheon on Saturday, December 7, from 11:00 AM to 12:30 PM. 🥂 🍷 🍲 🍔 🎉 Please feel free to reach out if you would like an invitation to our reception. We look forward to connecting with you soon. Stay tuned for further updates during the conference.
Join IFLI at the American Society of Hematology (ASH) Annual Meeting. We’re thrilled to be attending ASH2024! We look forward to collaborating with the leading minds in #hematology to support the latest in innovations and breakthroughs in the industry. The IFLI - Institute for Follicular Lymphoma Innovation team will be hosting a luncheon on Saturday, December 7, from 11:00 AM to 12:30 PM. 🥂 🍷 🍲 🍔 🎉 Please feel free to reach out if you would like an invitation to our reception. We look forward to connecting with you soon. Stay tuned for further updates during the conference.
IFLI - Institute for Follicular Lymphoma Innovation reposted this
- Professor of Immunology, AMU-APHM - Professor, Ecole Polytechnique - Chief Science Officer, Innate Pharma - President, Paris Saclay Cancer Cluster - ´Natural Killer Cells’ Chair, Fondation Gustave Roussy
Please check our last report in Science Immunology on IL-2v-armed tetraspecific NK cell engagers against B Cell lymphomas.
IFLI - Institute for Follicular Lymphoma Innovation reposted this
IFLI - Institute for Follicular Lymphoma Innovation is proud to announce a $2.1 million investment in a groundbreaking four-year research collaboration with Drs. Todd Fehniger and David Russler-Germain at Washington University in St. Louis. This funding supports the study titled “Using Circulating Tumor DNA #Sequencing to Advance Frontline Treatment of #Follicular #Lymphoma." Initially, IFLI provided a $1.3 million grant in 2022 to kickstart this important research. Now, with an additional $800,000, the study will expand to include 180 patients. These patients will undergo #PhasED-Seq #ctDNA-based measurable residual disease (#MRD) testing at pre-treatment, mid-treatment, and end-of-treatment stages. This approach aims to identify pre-treatment prognostic factors and assess the depth of response to therapy more accurately than traditional imaging methods. For more details on the Washington University study or IFLI, please visit IFLI’s website at https://www.i-fli.org/
IFLI - Institute for Follicular Lymphoma Innovation reposted this
Advancing Lymphoma Research.
IFLI - Institute for Follicular Lymphoma Innovation is proud to announce a $2.1 million investment in a groundbreaking four-year research collaboration with Drs. Todd Fehniger and David Russler-Germain at Washington University in St. Louis. This funding supports the study titled “Using Circulating Tumor DNA #Sequencing to Advance Frontline Treatment of #Follicular #Lymphoma." Initially, IFLI provided a $1.3 million grant in 2022 to kickstart this important research. Now, with an additional $800,000, the study will expand to include 180 patients. These patients will undergo #PhasED-Seq #ctDNA-based measurable residual disease (#MRD) testing at pre-treatment, mid-treatment, and end-of-treatment stages. This approach aims to identify pre-treatment prognostic factors and assess the depth of response to therapy more accurately than traditional imaging methods. For more details on the Washington University study or IFLI, please visit IFLI’s website at https://www.i-fli.org/
IFLI - Institute for Follicular Lymphoma Innovation is proud to announce a $2.1 million investment in a groundbreaking four-year research collaboration with Drs. Todd Fehniger and David Russler-Germain at Washington University in St. Louis. This funding supports the study titled “Using Circulating Tumor DNA #Sequencing to Advance Frontline Treatment of #Follicular #Lymphoma." Initially, IFLI provided a $1.3 million grant in 2022 to kickstart this important research. Now, with an additional $800,000, the study will expand to include 180 patients. These patients will undergo #PhasED-Seq #ctDNA-based measurable residual disease (#MRD) testing at pre-treatment, mid-treatment, and end-of-treatment stages. This approach aims to identify pre-treatment prognostic factors and assess the depth of response to therapy more accurately than traditional imaging methods. For more details on the Washington University study or IFLI, please visit IFLI’s website at https://www.i-fli.org/